Geniposide Promotes Osteoblast Differentiation and Fracture Healing in Rats by Regulating BMP-2/SMAD and PI3K/AKT Signaling Pathways
Acta Poloniae Pharmaceutica - Drug Research · 24.06.2026 · 84 (1) · 3-18
DOI: 10.32383/appdr/220495 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Poloniae Pharmaceutica - Drug Research, online erschienen am 24.06.2026. Verfasst von XvHong Ran und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Delayed fracture healing and nonunion are common clinical challenges, particularly prevalent among elderly patients. Geniposide (GEN) has shown potential to promote bone regeneration, yet its mechanisms in fracture healing remain poorly understood. Mouse MC3T3-E1 cells were employed to assess the osteogenic effects of GEN using a cell counting kit-8 assay, alkaline phosphatase (ALP) activity measurement, Alizarin Red S staining, and Western blot analysis. The interactions of signaling pathways were further explored using the bone morphogenetic protein (BMP) antagonist Noggin and the protein kinase B (AKT) inhibitor MK2206. Additionally, a rat femoral fracture model was established to evaluate the in vivo efficacy of GEN through histological staining techniques (hematoxylin and eosin, Masson’s trichrome), immunohistochemistry (targeting Runt-related transcription factor 2 [RUNX2], osteopontin [OPN], and osterix [OSX]), and biomechanical testing. GEN (≤ 50 μM) enhanced ALP activity, mineralized nodule formation, and the expression of osteogenic markers (RUNX2, OPN, and OSX) in a concentration-dependent manner. GEN activated the BMP-2/SMAD and phosphoinositide 3-Kinase (PI3K)/AKT pathways. MK2206 reduced levels of phosphorylated AKT and phosphorylated Mothers Against Decapentaplegic Homolog 1/5 (p-SMAD1/5) levels, whereas Noggin selectively suppressed p-SMAD1/5. In vivo, GEN improved fracture healing, increased mechanical strength per unit area, and promoted osteoblast aggregation and collagen deposition. By activating the PI3K/AKT and BMP/SMAD signaling pathways, GEN facilitates osteogenic differentiation and fracture repair, offering a promising therapeutic strategy for clinical fracture management.
Zitieren
APA
Ran, X., Liao, T., & Liu, Q. (2026). Geniposide Promotes Osteoblast Differentiation and Fracture Healing in Rats by Regulating BMP-2/SMAD and PI3K/AKT Signaling Pathways. Acta Poloniae Pharmaceutica - Drug Research, 84(1), 3-18. https://doi.org/10.32383/appdr/220495
Vancouver
Ran X, Liao T, Liu Q. Geniposide Promotes Osteoblast Differentiation and Fracture Healing in Rats by Regulating BMP-2/SMAD and PI3K/AKT Signaling Pathways. Acta Poloniae Pharmaceutica - Drug Research. 2026;84(1):3-18. doi:10.32383/appdr/220495
BibTeX
@article{Ran2026,
author = {Ran, XvHong and Liao, TianCheng and Liu, QiangFu},
title = {Geniposide Promotes Osteoblast Differentiation and Fracture Healing in Rats by Regulating BMP-2/SMAD and PI3K/AKT Signaling Pathways},
journal = {Acta Poloniae Pharmaceutica - Drug Research},
year = {2026},
volume = {84},
number = {1},
pages = {3--18},
doi = {10.32383/appdr/220495}
}
EUVIMED